KAPA (Kairos Pharma) Dividend Payout Ratio: 0.00 (As of Mar. 2026)


KAPA Kairos Pharma Ltd KAPA
15 GF Score
Price $0.38
View Full Analysis

What is Kairos Pharma Dividend Payout Ratio?

Kairos Pharma KAPA +7.48% 15 Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus rates KAPA with a GF Score™ of 15/100. Among 134 Biotechnology companies, Kairos Pharma ranks worse than 746267.91% on this metric.

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Kairos Pharma's Dividend Payout Ratio for the months ended in Mar. 2026 was 0.00.

The historical rank and industry rank for Kairos Pharma's Dividend Payout Ratio or its related term are showing as below:


KAPA's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.445
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2026-06-30), the Dividend Yield % of Kairos Pharma is 0.00%.

Kairos Pharma's Dividends per Share for the months ended in Mar. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.


Kairos Pharma (AMEX:KAPA) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.


Kairos Pharma Dividend Payout Ratio Related Terms


Kairos Pharma Dividend Payout Ratio Historical Data

* Premium members only.

The historical data trend for Kairos Pharma's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kairos Pharma Dividend Payout Ratio Chart

Kairos Pharma Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Dividend Payout Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Kairos Pharma Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Dividend Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

KAPA vs IMNN, HCWB, CURX: Dividend Payout Ratio Comparison

For the Biotechnology subindustry, Kairos Pharma's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kairos Pharma Dividend Payout Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kairos Pharma's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Kairos Pharma's Dividend Payout Ratio falls into.


KAPA
15GF Score
Kairos Pharma Ltd KAPA
Dividend Payout Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kairos Pharma Dividend Payout Ratio Calculation

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.

Kairos Pharma's Dividend Payout Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Dividend Payout Ratio=Dividends per Share (A: Dec. 2025 )/ EPS without NRI (A: Dec. 2025 )
=0/ -0.3
=N/A

Kairos Pharma's Dividend Payout Ratio for the quarter that ended in Mar. 2026 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Mar. 2026 )/ EPS without NRI (Q: Mar. 2026 )
=0/ -0.08
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Dividend Payout Ratio →
What does a Dividend Payout Ratio of 0.00 mean?
Kairos Pharma (KAPA) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Kairos Pharma and its competitors. According to the industry distribution chart, Kairos Pharma ranks #999999 out of 134 companies in the Biotechnology industry.
Is Kairos Pharma's Dividend Payout Ratio too high?
Kairos Pharma's current Dividend Payout Ratio is 0.00. Based on the distribution chart, Kairos Pharma ranks #999999 out of 134 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Kairos Pharma has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Kairos Pharma's Dividend Payout Ratio compare to IMNN and HCWB?
According to the Biotechnology industry distribution chart, Kairos Pharma ranks #999999 out of 134 companies for Dividend Payout Ratio. This places Kairos Pharma in the lower half of its industry. The industry median Dividend Payout Ratio is 0.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.45, based on 134 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Kairos Pharma and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kairos Pharma's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kairos Pharma stock overvalued right now?
Kairos Pharma (KAPA) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Kairos Pharma's overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Kairos Pharma (KAPA), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kairos Pharma Business Description

Address 2355 Westwood Boulevard, No. 139, Los Angeles, CA, USA, 90064
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
15GF Score

Get the complete analysis for KAPA

Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price